Open AccessInternational and russian experience in treating children’s flu
Author(s) -
В. Ф. Учайкин,
О В Кладова,
Ф С Харламова,
Н. Л. Вальтц,
Ю. В. Компаниец,
Н. Л. Гришкевич
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-17-137-145
Subject(s) - oseltamivir , medicine , clinical practice , resistance (ecology) , pediatrics , family medicine , political science , covid-19 , disease , infectious disease (medical specialty) , biology , ecology
The article presents an extensive clinical experience about the treatment and prevention of influenza by oseltamivir for children and adults including high-risk group patients through different countries around the world over the past 17 years. The article reveals the causes of resistance to oseltamivir with a relative evolution proportion. The new domestic drug Nomides (oseltamivir), which manufactured by Pharmasintez JSC (Russia) in accordance with the Good Manufacturing Practice (GMP), has been represented in the article by unique dosage forms 30 and 45 mg on the Russian market for childrens older than one years old.